Pharmaceutical GMP Readiness in India
India regulates medicines through the Central Drugs Standard Control Organisation (CDSCO) under the Drugs and Cosmetics Act 1940 and the Drugs and Cosmetics Rules 1945.
In Short
- CDSCO (headed by the Drugs Controller General of India, DCGI) is the central regulator; SLAs license manufacturing at state level.
- Manufacturing licences are issued by SLAs (Forms 25, 28, etc. depending on product class).
- Imports require a CDSCO Import Licence (Form 10/10A) and registration of the foreign manufacturer (Form 41).
GMP is set by Schedule M, comprehensively revised in 2023 to align closely with WHO TRS and PIC/S, with phased mandatory compliance starting 2024 (large units) and 2025 (MSME). State Licensing Authorities (SLAs) issue manufacturing licences; CDSCO handles imports, new drug approvals, and central inspections. India is NOT a PIC/S member but is an ICH observer. This guide covers the India layer.
Regulator and Legal Basis
CDSCO (headed by the Drugs Controller General of India, DCGI) is the central regulator; SLAs license manufacturing at state level. Drugs and Cosmetics Act 1940 + Rules 1945 are the statutory base; Schedule M (revised 2023) is the GMP standard.
More on regulator and Legal Basis
Export markets often require WHO-GMP, EU-GMP, or PIC/S equivalent certification on top of Schedule M.
Licensing model and revised Schedule M
Manufacturing licences are issued by SLAs (Forms 25, 28, etc. depending on product class). The revised Schedule M (Gazette notification 28 December 2023) introduces ICH Q10 PQS concepts, ICH Q9 risk management, a Pharmaceutical Quality System, qualification and validation per Annex 15-equivalent, and explicit data-integrity requirements.
More on licensing model and revised Schedule M
Large units (turnover > INR 250 crore) must comply by mid-2024; MSME by mid-2025.
Imports, Exports, and Certification
Imports require a CDSCO Import Licence (Form 10/10A) and registration of the foreign manufacturer (Form 41). For export, manufacturers typically hold WHO-GMP certificates issued by SLAs based on the WHO Certification Scheme, plus market-specific GMP certificates (EU, US FDA) earned through individual inspections.
Schedule L-1: the QC-lab counterpart to Schedule M
Schedule L-1 of the Drugs and Cosmetics Rules 1945 (inserted by GSR 780(E), 10 November 2008) is India's Good Laboratory Practices standard for pharmaceutical testing laboratories — in-house QC labs and third-party drug-testing labs approved under Rule 150-A. It sits alongside Schedule M: manufacturing is governed by Schedule M, batch release depends on QC data generated under Schedule L-1.
More on schedule L-1: the QC-lab counterpart to Schedule M
Requirements cover premises and layout, instrument qualification and calibration, SOPs, chemicals and reference standards, analyst qualification and training, method verification, chain of custody for samples, OOS/OOT investigation, and retention of raw analytical data (typically five years or one year past expiry, whichever is later). CDSCO and SLAs cite Schedule L-1 in GMP and Approved Testing Laboratory audits — common findings include data-integrity gaps, incomplete instrument qualification, and weak OOS investigation.
Inspection Style and Common Findings
CDSCO and SLA inspections increasingly use WHO/PIC/S classifications. Recent CDSCO risk-based inspections have focused on data integrity, sterile manufacturing, and not-of-standard-quality investigations.
More on inspection Style and Common Findings
Common findings: revised Schedule M gap closure (especially smaller units), data integrity, OOS investigation, and supplier qualification.
A 90–180 day India readiness path
- Days 0–30
confirm SLA licence scope and revised Schedule M applicability tier.
- Days 31–90
close revised Schedule M gaps — PQS, qualification/validation lifecycle, data-integrity controls, contamination control.
- Days 91–180
prepare for joint CDSCO/SLA inspection; for export buyers, run mock WHO-GMP or EU-GMP inspection.
Questions
Is India in PIC/S?
Not as of 2026. India is an ICH observer and the revised Schedule M brings GMP closer to PIC/S, but Indian GMP certificates are not formally recognized by PIC/S partner authorities.
What changed with the revised Schedule M?
It introduces a formal PQS (ICH Q10), risk management (ICH Q9), data-integrity expectations (ALCOA+), validation lifecycle, computerised system controls, and supplier qualification — moving Indian GMP closer to PIC/S. Compliance is phased through 2024–2025.
Do export markets accept Indian WHO-GMP certificates?
WHO-GMP issued by SLAs supports certain regulatory and procurement uses (notably WHO prequalification supply chains and many non-PIC/S markets). High-regulation markets (EU, US, UK) require their own GMP inspection or MRA equivalent.
What is Schedule L-1 and how does it relate to Schedule M?
Schedule L-1 is India's GLP standard for pharmaceutical testing labs — in-house QC labs and Rule 150-A approved third-party labs. Schedule M governs manufacturing; Schedule L-1 governs the lab that releases the batch. Both are inspected by CDSCO and SLAs and both must be met for compliant batch release.
Practical orientation, not legal advice. Rules differ by jurisdiction; your quality and compliance team decides what applies.
The Dietary Supplement Operations Guide
What the label says. What the batch proves.
- The rules and who decides
- Specification to finished batch
- Test, review, investigate
- Labels, samples and recall
Plus Evidence map and four worksheets.
Get the supplement guideWe ask for your name and email so we can handle this request. The full guide then opens on this site, ready to translate, print or save. Privacy policy. Practical orientation, not legal advice; your quality unit decides which rules apply.
UltimateFree guide
The Dietary Supplement Operations Guide
What the label says. What the batch proves.
Keep reading
Global Pharmaceutical GMP Readiness: Principles That Travel
Australia Pharmaceutical GMP Readiness: TGA and PIC/S GMP
Brazil Pharmaceutical GMP Readiness: ANVISA RDC 658/2022
Canada Drug GMP Readiness: Food and Drug Regulations Part C, Division 2
China Pharmaceutical GMP Readiness: NMPA and China GMP
EU GMP Guide: EudraLex Volume 4 Chapters, Annexes and Who Decides